Bioarctic granted Japanese patent for Parkinson’s disease candidate

Bioarctic has been granted a Japanese patent for its antibodies targeting Parkinson’s disease.

By Anders Göransson

August 31, 2023 1:42 PM

Swedish company Bioarctic has recently enjoyed great success in the field of Alzheimer’s disease, receiving full approval in the US for the drug lecanemab this summer. The company is also active in other therapeutic areas.

The patent now approved by the Japanese Patent Office (JPO) is for the drug candidate Ban0805, designed to stop or delay the progression of Parkinson’s disease.

The candidate involves a monoclonal antibody which, according to the company’s description, ‘selectively binds to and eliminates pathological aggregated forms called oligomers and protofibrils while protecting the physiological monomeric form of alpha-synuclein’.

A conducted phase I study has supported the continued development of the drug candidate in phase II with dosing once a month.

“The patent further strengthens Bioarctic’s patent portfolio and supports our important work to develop potential treatments for Parkinson’s disease and other synucleinopathies,” says the company’s CEO, Gunilla Osswald, in a press release.

The patent runs until 2041, with an option for extending the patent period until 2046.

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.